Loading…

Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy

Background The aim of this study was to define the clinicopathologic features of phospholipase A 2 receptor (PLA 2 R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment. Methods A tota...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental nephrology 2021-05, Vol.25 (5), p.488-500
Main Authors: Yeter, Hasan H., Isik Gonul, Ipek, Eraslan, Esra, Karacalik, Ceren, Ogut, Betul, Guz, Galip
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83
cites cdi_FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83
container_end_page 500
container_issue 5
container_start_page 488
container_title Clinical and experimental nephrology
container_volume 25
creator Yeter, Hasan H.
Isik Gonul, Ipek
Eraslan, Esra
Karacalik, Ceren
Ogut, Betul
Guz, Galip
description Background The aim of this study was to define the clinicopathologic features of phospholipase A 2 receptor (PLA 2 R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment. Methods A total of 201 patients were enrolled for baseline clinical and histopathological features and 102 patients with a clinical follow-up for more than 1 year were evaluated for outcomes. Immunohistochemical staining was performed with PLA 2 R and THSD7A antibodies on kidney biopsies and glomerular staining was evaluated. Results PLA 2 R expression was observed in 75% of the patients’ biopsies; however, THSD7A expression was present only in 7 patients’ biopsies (3.5%). No significant difference was found between histopathological and clinical features of PLA 2 R positive and negative patients, collectively. Glomerular PLA 2 R expression was significantly associated with complete and complete/partial remission with first-line treatment; however, overall complete, and complete/partial remission rates did not differ from PLA 2 R negative patients ( p  = 0.2 and p  = 0.8). Male gender, the presence of IgG4 staining and a necessity of immunosuppressive treatment were significantly associated with glomerular PLA 2 R expression. One patient, who developed end-stage renal disease, had glomerular expression for both PLA 2 R and THSD7A. Three patients with THSD7A-positive MN achieved complete remission. Conclusions The probability of achieving complete remission is high in patients with PLA 2 R-positive MN for whom the relapse rate was also higher. The overall renal outcome did not differ from PLA 2 R negative cases. Low incidence of THSD7A-positive MN reduces the possibility of future randomized controlled trials.
doi_str_mv 10.1007/s10157-020-02011-6
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2478773877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2478773877</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83</originalsourceid><addsrcrecordid>eNp9kc-KFDEQxoO44DrrC3gKePGSNdX_0jkOy6oLC170HDJJ9Uwv3UmbpMF5PN_M6p0FwYOHokL4fV9V8TH2HuQtSKk-ZZDQKiEruRWA6F6xa2hqJZTS-jW966YSoFp4w97m_CSl7HWrr9nv-2FAVzKPA19OMVNN42Iz8n3FEzpcSkzcBs_LKcX5QEQMfgy8nBcUwH2c7RiEi6FQH8ORqz3HX0vCnMcYOJHHKc6Y1skmfiDjGUPhM86HZAPSXLJKaMvzN6nInoZvAxMGO_G4Fkf6zehFFNfMAy60zmLL6XzDrgY7ZXz30nfsx-f773dfxeO3Lw93-0fh6qbrRGUb7ayXrdRNB8PQDupgETX0ukaJjfPgtZO-bb3vaoCqt1Wte607O1Tg-3rHPl58lxR_rpiLmcfscJroDFrJVI3qlaq32rEP_6BPcU10DVEtSK01ZURUdaFcijknHMySxtmmswFptlTNJVVDiZrnVE1HovoiygSHI6a_1v9R_QFrnam6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2510999201</pqid></control><display><type>article</type><title>Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy</title><source>Springer Link</source><creator>Yeter, Hasan H. ; Isik Gonul, Ipek ; Eraslan, Esra ; Karacalik, Ceren ; Ogut, Betul ; Guz, Galip</creator><creatorcontrib>Yeter, Hasan H. ; Isik Gonul, Ipek ; Eraslan, Esra ; Karacalik, Ceren ; Ogut, Betul ; Guz, Galip</creatorcontrib><description>Background The aim of this study was to define the clinicopathologic features of phospholipase A 2 receptor (PLA 2 R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment. Methods A total of 201 patients were enrolled for baseline clinical and histopathological features and 102 patients with a clinical follow-up for more than 1 year were evaluated for outcomes. Immunohistochemical staining was performed with PLA 2 R and THSD7A antibodies on kidney biopsies and glomerular staining was evaluated. Results PLA 2 R expression was observed in 75% of the patients’ biopsies; however, THSD7A expression was present only in 7 patients’ biopsies (3.5%). No significant difference was found between histopathological and clinical features of PLA 2 R positive and negative patients, collectively. Glomerular PLA 2 R expression was significantly associated with complete and complete/partial remission with first-line treatment; however, overall complete, and complete/partial remission rates did not differ from PLA 2 R negative patients ( p  = 0.2 and p  = 0.8). Male gender, the presence of IgG4 staining and a necessity of immunosuppressive treatment were significantly associated with glomerular PLA 2 R expression. One patient, who developed end-stage renal disease, had glomerular expression for both PLA 2 R and THSD7A. Three patients with THSD7A-positive MN achieved complete remission. Conclusions The probability of achieving complete remission is high in patients with PLA 2 R-positive MN for whom the relapse rate was also higher. The overall renal outcome did not differ from PLA 2 R negative cases. Low incidence of THSD7A-positive MN reduces the possibility of future randomized controlled trials.</description><identifier>ISSN: 1342-1751</identifier><identifier>EISSN: 1437-7799</identifier><identifier>DOI: 10.1007/s10157-020-02011-6</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Basement membranes ; Biopsy ; Clinical trials ; End-stage renal disease ; Immunoglobulin G ; Kidney diseases ; Medicine ; Medicine &amp; Public Health ; Membranous nephropathy ; Nephrology ; Nephropathy ; Original Article ; Patients ; Phospholipase A2 ; Remission ; Thrombospondin ; Urology</subject><ispartof>Clinical and experimental nephrology, 2021-05, Vol.25 (5), p.488-500</ispartof><rights>Japanese Society of Nephrology 2021</rights><rights>Japanese Society of Nephrology 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83</citedby><cites>FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83</cites><orcidid>0000-0002-5787-1048</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Yeter, Hasan H.</creatorcontrib><creatorcontrib>Isik Gonul, Ipek</creatorcontrib><creatorcontrib>Eraslan, Esra</creatorcontrib><creatorcontrib>Karacalik, Ceren</creatorcontrib><creatorcontrib>Ogut, Betul</creatorcontrib><creatorcontrib>Guz, Galip</creatorcontrib><title>Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy</title><title>Clinical and experimental nephrology</title><addtitle>Clin Exp Nephrol</addtitle><description>Background The aim of this study was to define the clinicopathologic features of phospholipase A 2 receptor (PLA 2 R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment. Methods A total of 201 patients were enrolled for baseline clinical and histopathological features and 102 patients with a clinical follow-up for more than 1 year were evaluated for outcomes. Immunohistochemical staining was performed with PLA 2 R and THSD7A antibodies on kidney biopsies and glomerular staining was evaluated. Results PLA 2 R expression was observed in 75% of the patients’ biopsies; however, THSD7A expression was present only in 7 patients’ biopsies (3.5%). No significant difference was found between histopathological and clinical features of PLA 2 R positive and negative patients, collectively. Glomerular PLA 2 R expression was significantly associated with complete and complete/partial remission with first-line treatment; however, overall complete, and complete/partial remission rates did not differ from PLA 2 R negative patients ( p  = 0.2 and p  = 0.8). Male gender, the presence of IgG4 staining and a necessity of immunosuppressive treatment were significantly associated with glomerular PLA 2 R expression. One patient, who developed end-stage renal disease, had glomerular expression for both PLA 2 R and THSD7A. Three patients with THSD7A-positive MN achieved complete remission. Conclusions The probability of achieving complete remission is high in patients with PLA 2 R-positive MN for whom the relapse rate was also higher. The overall renal outcome did not differ from PLA 2 R negative cases. Low incidence of THSD7A-positive MN reduces the possibility of future randomized controlled trials.</description><subject>Basement membranes</subject><subject>Biopsy</subject><subject>Clinical trials</subject><subject>End-stage renal disease</subject><subject>Immunoglobulin G</subject><subject>Kidney diseases</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Membranous nephropathy</subject><subject>Nephrology</subject><subject>Nephropathy</subject><subject>Original Article</subject><subject>Patients</subject><subject>Phospholipase A2</subject><subject>Remission</subject><subject>Thrombospondin</subject><subject>Urology</subject><issn>1342-1751</issn><issn>1437-7799</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kc-KFDEQxoO44DrrC3gKePGSNdX_0jkOy6oLC170HDJJ9Uwv3UmbpMF5PN_M6p0FwYOHokL4fV9V8TH2HuQtSKk-ZZDQKiEruRWA6F6xa2hqJZTS-jW966YSoFp4w97m_CSl7HWrr9nv-2FAVzKPA19OMVNN42Iz8n3FEzpcSkzcBs_LKcX5QEQMfgy8nBcUwH2c7RiEi6FQH8ORqz3HX0vCnMcYOJHHKc6Y1skmfiDjGUPhM86HZAPSXLJKaMvzN6nInoZvAxMGO_G4Fkf6zehFFNfMAy60zmLL6XzDrgY7ZXz30nfsx-f773dfxeO3Lw93-0fh6qbrRGUb7ayXrdRNB8PQDupgETX0ukaJjfPgtZO-bb3vaoCqt1Wte607O1Tg-3rHPl58lxR_rpiLmcfscJroDFrJVI3qlaq32rEP_6BPcU10DVEtSK01ZURUdaFcijknHMySxtmmswFptlTNJVVDiZrnVE1HovoiygSHI6a_1v9R_QFrnam6</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Yeter, Hasan H.</creator><creator>Isik Gonul, Ipek</creator><creator>Eraslan, Esra</creator><creator>Karacalik, Ceren</creator><creator>Ogut, Betul</creator><creator>Guz, Galip</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5787-1048</orcidid></search><sort><creationdate>20210501</creationdate><title>Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy</title><author>Yeter, Hasan H. ; Isik Gonul, Ipek ; Eraslan, Esra ; Karacalik, Ceren ; Ogut, Betul ; Guz, Galip</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Basement membranes</topic><topic>Biopsy</topic><topic>Clinical trials</topic><topic>End-stage renal disease</topic><topic>Immunoglobulin G</topic><topic>Kidney diseases</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Membranous nephropathy</topic><topic>Nephrology</topic><topic>Nephropathy</topic><topic>Original Article</topic><topic>Patients</topic><topic>Phospholipase A2</topic><topic>Remission</topic><topic>Thrombospondin</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yeter, Hasan H.</creatorcontrib><creatorcontrib>Isik Gonul, Ipek</creatorcontrib><creatorcontrib>Eraslan, Esra</creatorcontrib><creatorcontrib>Karacalik, Ceren</creatorcontrib><creatorcontrib>Ogut, Betul</creatorcontrib><creatorcontrib>Guz, Galip</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yeter, Hasan H.</au><au>Isik Gonul, Ipek</au><au>Eraslan, Esra</au><au>Karacalik, Ceren</au><au>Ogut, Betul</au><au>Guz, Galip</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy</atitle><jtitle>Clinical and experimental nephrology</jtitle><stitle>Clin Exp Nephrol</stitle><date>2021-05-01</date><risdate>2021</risdate><volume>25</volume><issue>5</issue><spage>488</spage><epage>500</epage><pages>488-500</pages><issn>1342-1751</issn><eissn>1437-7799</eissn><abstract>Background The aim of this study was to define the clinicopathologic features of phospholipase A 2 receptor (PLA 2 R) and/or thrombospondin type-1 domain-containing 7A (THSD7A) associated membranous nephropathy(MN) focusing on their impact to disease relapse and response to treatment. Methods A total of 201 patients were enrolled for baseline clinical and histopathological features and 102 patients with a clinical follow-up for more than 1 year were evaluated for outcomes. Immunohistochemical staining was performed with PLA 2 R and THSD7A antibodies on kidney biopsies and glomerular staining was evaluated. Results PLA 2 R expression was observed in 75% of the patients’ biopsies; however, THSD7A expression was present only in 7 patients’ biopsies (3.5%). No significant difference was found between histopathological and clinical features of PLA 2 R positive and negative patients, collectively. Glomerular PLA 2 R expression was significantly associated with complete and complete/partial remission with first-line treatment; however, overall complete, and complete/partial remission rates did not differ from PLA 2 R negative patients ( p  = 0.2 and p  = 0.8). Male gender, the presence of IgG4 staining and a necessity of immunosuppressive treatment were significantly associated with glomerular PLA 2 R expression. One patient, who developed end-stage renal disease, had glomerular expression for both PLA 2 R and THSD7A. Three patients with THSD7A-positive MN achieved complete remission. Conclusions The probability of achieving complete remission is high in patients with PLA 2 R-positive MN for whom the relapse rate was also higher. The overall renal outcome did not differ from PLA 2 R negative cases. Low incidence of THSD7A-positive MN reduces the possibility of future randomized controlled trials.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><doi>10.1007/s10157-020-02011-6</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-5787-1048</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1342-1751
ispartof Clinical and experimental nephrology, 2021-05, Vol.25 (5), p.488-500
issn 1342-1751
1437-7799
language eng
recordid cdi_proquest_miscellaneous_2478773877
source Springer Link
subjects Basement membranes
Biopsy
Clinical trials
End-stage renal disease
Immunoglobulin G
Kidney diseases
Medicine
Medicine & Public Health
Membranous nephropathy
Nephrology
Nephropathy
Original Article
Patients
Phospholipase A2
Remission
Thrombospondin
Urology
title Effects of phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A expression in glomerular basement membranes on treatment response and renal outcome in membranous nephropathy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T13%3A45%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20phospholipase%20A2%20receptor%20and%20thrombospondin%20type-1%20domain-containing%207A%20expression%20in%20glomerular%20basement%20membranes%20on%20treatment%20response%20and%20renal%20outcome%20in%20membranous%20nephropathy&rft.jtitle=Clinical%20and%20experimental%20nephrology&rft.au=Yeter,%20Hasan%20H.&rft.date=2021-05-01&rft.volume=25&rft.issue=5&rft.spage=488&rft.epage=500&rft.pages=488-500&rft.issn=1342-1751&rft.eissn=1437-7799&rft_id=info:doi/10.1007/s10157-020-02011-6&rft_dat=%3Cproquest_cross%3E2478773877%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3466-2a49cad0509461ff5f7baee91893e0e4cd1d9c0d55dd631128a2398996af21d83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2510999201&rft_id=info:pmid/&rfr_iscdi=true